Literature DB >> 24419343

Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.

Nicolas Sluis-Cremer1, Kelly D Huber, Chanson J Brumme, P Richard Harrigan.   

Abstract

We characterized the relative fitness of multiple nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI)-resistant HIV-1 variants in the presence of etravirine (ETV), rilpivirine (RPV), and/or the nucleoside RT inhibitor emtricitabine (FTC) by simultaneous competitive culture and 454 deep sequencing. The E138A substitution, typically associated with decreased virologic responses to ETV- and RPV-containing regimens, confers a clear fitness advantage to the virus in the presence of FTC and decreases FTC susceptibility 4.7-fold.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24419343      PMCID： PMC4023788          DOI： 10.1128/AAC.02114-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Authors:  Laurence Rimsky; Johan Vingerhoets; Veerle Van Eygen; Joseph Eron; Bonaventura Clotet; Annemie Hoogstoel; Katia Boven; Gaston Picchio
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

2.  Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing.

Authors:  Chanson J Brumme; Kelly D Huber; Winnie Dong; Art F Y Poon; P Richard Harrigan; Nicolas Sluis-Cremer
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

3.  Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.

Authors:  Zixin Hu; Daniel R Kuritzkes
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

4.  Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.

Authors:  Hong-Tao Xu; Eugene L Asahchop; Maureen Oliveira; Peter K Quashie; Yudong Quan; Bluma G Brenner; Mark A Wainberg
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.

Authors:  Rima Kulkarni; Kerim Babaoglu; Eric B Lansdon; Laurence Rimsky; Veerle Van Eygen; Gaston Picchio; Evguenia Svarovskaia; Michael D Miller; Kirsten L White
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

6.  96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.

Authors:  Laurence Rimsky; Veerle Van Eygen; Annemie Hoogstoel; Marita Stevens; Katia Boven; Gaston Picchio; Johan Vingerhoets
Journal:  Antivir Ther       Date:  2013-05-28

7.  TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Authors:  Hilde Azijn; Ilse Tirry; Johan Vingerhoets; Marie-Pierre de Béthune; Guenter Kraus; Katia Boven; Dirk Jochmans; Elke Van Craenenbroeck; Gaston Picchio; Laurence T Rimsky
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

8.  The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.

Authors:  Zandrea Ambrose; Brian D Herman; Chih-Wei Sheen; Shannon Zelina; Katie L Moore; Gilda Tachedjian; Dwight V Nissley; Nicolas Sluis-Cremer
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103
  8 in total
  4 in total

1.  HIV-1 clinical isolates with the E138A substitution in reverse transcriptase show full susceptibility to emtricitabine and other nucleoside reverse transcriptase inhibitors.

Authors:  Danielle P Porter; Rima Kulkarni; Kirsten L White
Journal:  Antimicrob Agents Chemother       Date:  2014-09       Impact factor: 5.191

2.  Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.

Authors:  Kevin Melody; Sarah McBeth; Christopher Kline; Angela D M Kashuba; John W Mellors; Zandrea Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

3.  Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures.

Authors:  Priya Srinivasan; John A Moss; Manjula Gunawardana; Scott A Churchman; Flora Yang; Chuong T Dinh; James M Mitchell; Jining Zhang; Rob Fanter; Christine S Miller; Irina Butkyavichene; Janet M McNicholl; Thomas J Smith; Marc M Baum; James M Smith
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

4.  Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.

Authors:  Kevin Melody; Chandra N Roy; Christopher Kline; Mackenzie L Cottrell; Dwayne Evans; Kathleen Shutt; Pleuni S Pennings; Brandon F Keele; Moses Bility; Angela D M Kashuba; Zandrea Ambrose
Journal:  J Virol       Date:  2020-03-31       Impact factor: 6.549
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.